Other languages MiMedx Group, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
7.31 ^USD	+18.67%		+13.69%	-16.65%

04-30	Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
04-30	Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M	MT

MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	03-27
MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation from FDA	03-27
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	03-20
MiMedx Launches E-Commerce Platform	03-13
Mimedx Introduces E-Commerce and Account Management Platform	03-13
MiMedx Group, Inc. Announces Appointment of New Independent Directors	03-04
Spectral AI Names Peter Carlson Chief Executive Officer; Reaffirms 2024 Preliminary Revenue Guidance	03-01
MiMedx Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
MiMedx Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28
MÄRKTE USA/Abflauende Zinssenkungsfantasie belastet Aktien	01-02
LATE BRIEFING - Unternehmen und Märkte	01-02
MÄRKTE USA/Abflauende Zinssenkungsfantasie drückt Wall Street ins Minus	01-02
MÄRKTE USA/Jahresstart im Minus - Zinssenkungsfantasie flaut ab	01-02
MÄRKTE USA/Verhaltener Start erwartet - China-Daten belasten	01-02
MIDDAY BRIEFING - Unternehmen und Märkte	01-02
MARKT USA/Verhaltener Start erwartet - China-Daten belasten	01-02
MORNING BRIEFING - USA/Asien	01-02
MiMedx reports US FDA warning letter for Axiofill, shares drop	12-29
MiMedx says US FDA's warning letter for Axiofill not related to safety	12-29
MiMedx Group Converts Series B Preferred Stock to Common Stock, Adds 30 Million Shares	12-28

No results for this search